Clinical Trial Search

Primary: Maximum Concentration (Cmax) of Aprepitant in Participants 0 to <2 Years of Age — 3550 ng/mL

Primary: Number of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 2; 0 Participants

Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 — 10.3; 37.9; 37.2…

Primary: Hospital Re-admissions Analyzed by Poisson Regression — 17; 4; 21; 5 Hospital Readmission — p=0.030

Primary: Pancreatic and Liver Triglyceride (Fat) Content — 6.44; 2.08 percent

Primary: Number of Subjects With Any Episodes of Herpes Zoster (HZ) — 17; 6; 23; 169 Participants — p=<0.0001

Primary: Caregiver Anxiety: Change From Baseline to Post-Intervention Exit — -0.9; -2.0; -0.7 units on a scale — p=0.002

Primary: Fold Change in Long Chain Fatty Acids — 1; 0.76 Fold Change in long chain fatty acids

Primary: Perceived Pain Level — 5.81; 4.39 units on a scale — p=<0.0001

Primary: Patient-centered Outcome Measure = Self-reported Hunger — 40.6; 40.8 units on a scale — p=0.30

Primary: Percentage of Participants With PSA Response — 39.7; 15.9; 55.6 percentage of participants

Primary: Best Response Rate (Partial Response [PR] + Complete Response [CR]) — 6; 14 Participants — p=0.035

Primary: Geometric Mean Titre (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks Post-vaccination — 395.3; 391.7 gpELISA units/mL — p=<0.001

Primary: Healing Touch Will Improve Total Sleep Time — 352.9; 368.2; 383.1; 367.2 minutes

Primary: Disease Free Survival. — 81.0; 79.6 percentage of patients